An Insertion Variant in CRH Confers an Increased Risk of Central Serous Chorioretinopathy

Invest Ophthalmol Vis Sci. 2022 Aug 2;63(9):9. doi: 10.1167/iovs.63.9.9.

Abstract

Purpose: To identify a novel corticotropin-releasing hormone (CRH) gene variant relevant in patients with central serous chorioretinopathy (CSC).

Methods: We performed a genetic study of CSC in families and sporadic cases with controls. Using whole-exome sequencing and linkage analysis, we identified a heterozygous insertion variant, Gln52insPro, in the CRH gene that cosegregated in two Chinese families with CSC. This variant was evaluated among an additional 1307 patients with CSC and 1438 ethnicity-matched control individuals from three independent Chinese cohorts.

Results: The CRH variant was strongly associated with CSC in these cohorts of Chinese patients (Pmeta = 1.24 × 10-11; odds ratio, 3.01; 95% confidence interval, 2.15-4.21). The risk variant Gln52insPro decreased CRH gene expression.

Conclusions: Our results implicate the hypothalamic-pituitary-adrenal stress response system in the pathogenesis of CSC and provide a novel rationale for therapeutic intervention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Asian People
  • Central Serous Chorioretinopathy* / diagnosis
  • Central Serous Chorioretinopathy* / genetics
  • Genetic Linkage
  • Humans
  • Hypothalamo-Hypophyseal System / physiology
  • Pituitary-Adrenal System / physiology